ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
Author(s): Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K
Source: CANCER RESEARCH    Volume: 60    Issue: 5    Pages: 1306-1311    Published: MAR 1 2000  
Times Cited: 758     References: 27     
Abstract: We provide evidence that cyclooxygenase (COX)-2-derived prostaglandins contribute to tumor growth by inducing newly formed blood vessels (neoangiogenesis) that sustain tumor cell viability and growth. COX-2 is expressed within human tumor neovasculature as well as in neoplastic cells present in human colon, breast, prostate, and lung cancer biopsy tissue. COX-I is broadly distributed in normal, as wed as in neoplastic, tissues, The contribution of COX-2 to human tumor growth was indicated by the ability of celecoxib, an agent that inhibits the COX-2 enzyme, to suppress growth of lung and colon tumors implanted into recipient mice. Mechanistically, celecoxib demonstrated a potent antiangiogenic activity. In a rat model of angiogenesis, we observe that corneal blood vessel Formation is suppressed by celecoxib, but not by a COX-I inhibitor. These and other data indicate that COX-2 and COX-2-derived prostaglandins may play a major role in development of cancer through numerous biochemical mechanisms, including stimulation of tumor cell growth and neovascularization, The ability of celecoxib to block angiogenesis and suppress tumor growth suggests a novel application of this anti-inflammatory drug in the treatment of human cancer.
Document Type: Article
Language: English
Reprint Address: Masferrer, JL (reprint author), GD Searle Monsanto Co, T3G,800 N Lindbergh Blvd, St Louis, MO 63167 USA
Addresses:
1. GD Searle Monsanto Co, St Louis, MO 63167 USA
Publisher: AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202 USA
Subject Category: Oncology
IDS Number: 293RA
ISSN: 0008-5472
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo